A Phase 2 interventional study of 17beta Estradiol and Transdermal placebo patch in Estrogen Deficiency, Cardiovascular Disease (CVD) and Functional Hypothalamic Amenorrhea, sponsored by Cedars-Sinai Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Cedars-Sinai Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether young women with functional hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for pre-clinical cardiovascular disease (CVD).
For this study, the investigators will measuring vascular function and inflammatory markers on:
Premenopausal HypoE participants (women with functional hypothalamic amenorrhea) will be randomized to use either an estrogen patch or a placebo patch (no active medicine) for 12 weeks, followed by estrogen or placebo patch plus progesterone or placebo pills for 2 additional weeks. The investigators are looking to see if estrogen improves vascular and inflammation.
Study Aims:
In a randomized, double-blind placebo-controlled trial in premenopausal HypoE women (women with FHA) the investigators will test 12 weeks of transdermal estradiol 0.1 mg/day patch or placebo followed by 2 weeks of estradiol plus progesterone 200mg (for endometrial safety) on vascular endothelial function and immune-mediated inflammation versus placebo. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
The investigators will be using non-invasive tests to measure vascular function to measures reactive hyperemic index (RHI) using peripheral arterial tonometry (PAT)
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's enrollment of 29 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For premenopausal Hypo E and normal control women, inclusions include:
For recently menopausal women inclusions include:
Exclusion Criteria:
For premenopausal Hypo E and normal control women exclusions include:
For HypoE women, exclusion criteria include:
For recently menopausal women exclusions also include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
17Beta Estradiol (0.1mg/day) , Progesterone (100mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 100mg is a peanut based product
Drug: 17beta Estradiol · Drug: Progesterone
Placebo Transdermal Patch, Placebo Pill
Drug: Transdermal placebo patch · Drug: Placebo Pill
Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
Also known as: Estradiol Transdermal Patch, Vivelle-Dot
Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
Also known as: Prometrium
After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
Also known as: Placebo Oral Pill
Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry
Change in PAT measured as reactive hyperemia index (RHI) from baseline to week 12 on treatment or placebo. Reactive hyperemia index (RHI) is the post-to-pre occlusion PAT signal ratio in the occluded arm, relative to the same ratio in the control arm, corrected for baseline vascular tone of the occluded arm calculated by taking the ratio of the pulse amplitude during the hyperemic phase (after a period of blood flow occlusion) to the baseline pulse amplitude. The values below \<1.67 are abnormal and suggest impaired endothelial function or endothelial dysfunction.
Time frame: Baseline, week 12 on trial
Serum Inflammatory Markers
Change in serum cortisol from baseline to week 12 on treatment or placebo
Time frame: Change in serum cortisol from baseline to week 12 on treatment or placebo
Serum Estradiol Levels
Week 12 serum estradiol levels
Time frame: Serum estradiol levels after 12 week of treatment vs placebo
Quality of Life (Questionnaire)
Short-Form Health Survey 12 (SF-12) was reported as the mental component score (MCS) and physical component score (PCS). Each scale ranges from 0 to 100. For both PCS and MCS, higher values represent better outcomes, indicating superior physical or mental health, respectively. Lower scores suggest poorer outcomes in the respective domains. Scores above 50 for either PCS or MCS are generally considered above the population average for health-related quality of life, as the scales are often normed to a mean of 50 with a standard deviation of 10 in general population studies. Scores below 50 suggest below-average physical or mental health, with the degree of deviation providing further insight into the severity of physical or mental health challenges.
Time frame: Change in quality of life scores after 12 week of treatment vs placebo
Depression
Patient Health Questionnaire (PHQ-9) total score ranges from 0 to 27. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating greater severity of depressive symptoms. Interpretation of Scores: * 0-4: Minimal or no depression * 5-9: Mild depression * 10-14: Moderate depression * 15-19: Moderately severe depression * 20-27: Severe depression
Time frame: Change in PHQ-9 Scores after 12 week of treatment vs placebo
Change in Insomnia Severity Index After 12 Week of Treatment vs Placebo
Change in Insomnia Severity Index after 12 week of treatment vs placebo. Insomnia Severity Index (ISI) total score ranges from 0 to 28.
Time frame: Insomnia score after 12 week of treatment vs placebo
Anxiety
Overall Anxiety Severity and Impairment Scale (OASIS) total score ranges from 0 to 20, with each of the 5 items scored on a scale of 0 (no anxiety or impairment) to 4 (extreme anxiety or impairment). Higher scores indicate greater severity and functional impairment related to anxiety. The OASIS scores can be categorized as follows: * 0-4: Minimal or no anxiety * 5-9: Mild anxiety * 10-14: Moderate anxiety with some functional impairment * 15-20: Severe anxiety with significant functional impairment.
Time frame: Change in Anxiety Scores after 12 week of treatment vs placebo
Stress
Cohen Perceived Stress Scale (PSS) ranges from 0 to 40, with each of the 10 items scored on a scale of 0 (never) to 4 (very often). Higher scores reflect higher levels of perceived stress. The PSS scores can be categorized as follows: * 0-13: Low perceived stress * 14-26: Moderate perceived stress * 27-40: High perceived stress
Time frame: Change in stress scores after 12 week of treatment vs placebo
Change in Serum Estradiol Levels
Change from Baseline to week 12 serum estradiol levels
Time frame: change in estradiol after 12 week of treatment vs placebo
Serum Inflammatory Markers
Change in serum hsCRP from baseline to week 12 on treatment or placebo
Time frame: Change in serum hsCRP from baseline to week 12 on treatment or placebo
| Milestone | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Started | 14 | 15 |
| Completed | 12 | 12 |
| Not completed | 2 | 3 |
Change in PAT measured as reactive hyperemia index (RHI) from baseline to week 12 on treatment or placebo. Reactive hyperemia index (RHI) is the post-to-pre occlusion PAT signal ratio in the occluded arm, relative to the same ratio in the control arm, corrected for baseline vascular tone of the occluded arm calculated by taking the ratio of the pulse amplitude during the hyperemic phase (after a period of blood flow occlusion) to the baseline pulse amplitude. The values below \<1.67 are abnormal and suggest impaired endothelial function or endothelial dysfunction.
| change of RHI | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry | 0.20 ± 0.52 | 0.25 ± 0.64 |
Change in serum cortisol from baseline to week 12 on treatment or placebo
| µg/dL | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Serum Inflammatory Markers | -0.4 (-4.57 to 1.70) | 3.1 (0.2 to 5.96) |
Week 12 serum estradiol levels
| pg/mL | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Serum Estradiol Levels | 108.0 (85.8 to 165.0) | 36.5 (16.7 to 51.2) |
Short-Form Health Survey 12 (SF-12) was reported as the mental component score (MCS) and physical component score (PCS). Each scale ranges from 0 to 100. For both PCS and MCS, higher values represent better outcomes, indicating superior physical or mental health, respectively. Lower scores suggest poorer outcomes in the respective domains. Scores above 50 for either PCS or MCS are generally considered above the population average for health-related quality of life, as the scales are often normed to a mean of 50 with a standard deviation of 10 in general population studies. Scores below 50 suggest below-average physical or mental health, with the degree of deviation providing further insight into the severity of physical or mental health challenges.
| score on a scale | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| SF12-PCS | 2.14 ± 7.97 | -0.45 ± 4.44 |
| SF12-MCS | 1.83 ± 11.66 | 2.69 ± 5.99 |
Patient Health Questionnaire (PHQ-9) total score ranges from 0 to 27. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating greater severity of depressive symptoms. Interpretation of Scores: * 0-4: Minimal or no depression * 5-9: Mild depression * 10-14: Moderate depression * 15-19: Moderately severe depression * 20-27: Severe depression
| score on a scale | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Depression | -0.67 ± 3.52 | -0.08 ± 2.09 |
Change in Insomnia Severity Index after 12 week of treatment vs placebo. Insomnia Severity Index (ISI) total score ranges from 0 to 28.
| score on a scale | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Change in Insomnia Severity Index After 12 Week of Treatment vs Placebo | 8.0 ± 5.7 | 3.9 ± 4.0 |
Overall Anxiety Severity and Impairment Scale (OASIS) total score ranges from 0 to 20, with each of the 5 items scored on a scale of 0 (no anxiety or impairment) to 4 (extreme anxiety or impairment). Higher scores indicate greater severity and functional impairment related to anxiety. The OASIS scores can be categorized as follows: * 0-4: Minimal or no anxiety * 5-9: Mild anxiety * 10-14: Moderate anxiety with some functional impairment * 15-20: Severe anxiety with significant functional impairment.
| score on a scale | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Anxiety | -0.31 ± 3.3 | -0.54 ± 2.07 |
Cohen Perceived Stress Scale (PSS) ranges from 0 to 40, with each of the 10 items scored on a scale of 0 (never) to 4 (very often). Higher scores reflect higher levels of perceived stress. The PSS scores can be categorized as follows: * 0-13: Low perceived stress * 14-26: Moderate perceived stress * 27-40: High perceived stress
| score on a scale | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Stress | -0.49 ± 3.69 | -0.46 ± 3.41 |
Change from Baseline to week 12 serum estradiol levels
| pg/mL | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Change in Serum Estradiol Levels | 84 (44.3 to 144.8) | -4.7 (-14.6 to 4.25) |
Change in serum hsCRP from baseline to week 12 on treatment or placebo
| mg/L | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill |
|---|---|---|
| Serum Inflammatory Markers | 0.0857 (0.017 to 0.174) | 0.0322 (-0.00021 to 0.172) |
Collected over For the length of the study enrollment, 14 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 17Beta Estradiol, Progesterone | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Transdermal Placebo Patch, Placebo Pill | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Age, Continuous(years) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Mean | 27 ± 6.7 | 25.1 ± 6.1 | 26.0 ± 6.3 |
| Sex/Gender, Customized(Participants) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Female | 14 | 15 | 29 |
| Race (NIH/OMB)(Participants) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 8 | 18 |
| More than one race | 1 | 5 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| BMI(kg/m^2) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Mean | 21.7 ± 3.7 | 21.4 ± 3.1 | 21.5 ± 3.3 |
| Waist(inches) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Mean | 27.1 ± 2.1 | 27.1 ± 3.7 | 27.1 ± 2.99 |
| Hip(inches) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Mean | 34.0 ± 2.1 | 34.4 ± 3.7 | 34.2 ± 3.0 |
| Age at Menarche(years) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Mean | 13.1 ± 1.8 | 12.9 ± 1.4 | 12.96 ± 1.6 |
| Serum Estradiol(pg/mL) | 17Beta Estradiol, Progesterone | Transdermal Placebo Patch, Placebo Pill | Total |
|---|---|---|---|
| Median | 24 (12 to 42) | 30 (26 to 38) | 25 (18.5 to 35) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Feb 2023, 73 months.
Results were first posted in Feb 2025, 2 years after primary completion. A results delay was requested in Jan 2024.
Of 60 non-industry phase 2 interventional studies under Cardiovascular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 73. This study's 73 months is above that.
Counting every sponsor, half of 84 studies reached it within 28 months; a quarter within 16 and three quarters within 61.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Progesterone